Future Anticoagulants - report from ISTH 2026

Dr. Marco Donadini highlights the next generation of antithrombotic therapies at the ISTH 2026 Congress, featuring these breakthrough presentations:- A Synthetic, Allosteric, Highly Selective, Reversible Inhibitor of Human Factor XIa for Venous and Lung (Cancer-Associated) Thrombosis – Umesh Desai (Richmond, US)- EXocite ACTive site (EXACT) Inhibitors as Potent RNA Aptamer-Based Anticoagulants Targeting Various Coagulation Factors – Jeffrey Clancy (Durham, US)- Efficacy-Safety Paradox of Next-Gen Factor XI/XIa Inhibitors: Meta-Analysis of Phase 2 and 3 Trials – Rahul Falodia (Jodhpur, India)- BAY 3389934: A Dual Factor IIa/Xa Inhibitor – Nicole Juffermans (Rotterdam, The Netherlands)- REGN9533, a monoclonal antibody targeting Factor XII (FXII), Phase 1 study – Frédéric Vanhoutte (Antwerp, Belgium)Video: https://medicaldigest.org/scientific-contents/interview:future-anticoagulants